Larotrectinib Subgroup Analyses Demonstrate Long-Term Efficacy, Safety Profile in NTRK Gene Fusion Cancer

Findings presented at the American Society of Clinical Oncology (ASCO) 2023 meeting show the long-term efficacy and safety profile of larotrectinib (Vitrakvi; Bayer) in solid tumors with NTRK gene fusion.

Related Keywords

United States ,American ,Iain Webb ,Nathan Devery ,Us Medical Affairs ,American Society Of Clinical Oncology ,American Society ,Clinical Oncology ,